CURRICULUM VITAE
EVA ESTÉBANEZ PERPIÑÁ, Ph.D.
September 2022

WORK ADDRESS

Institute of Biomedicine (IBUB) of the University of Barcelona (UB)
Baldiri Reixac, 15-21, 08028-Barcelona, Spain Phone: 93-403-1119 (office)
http://www.ub.edu/ibub/eva_estebanez.html e-mail: evaestebanez@ub.edu

EDUCATION

1998-2002	Ph.D. at the Max-Planck-Institut fur Biochemie (MPI) Munich, Germany Prof. Dr. Robert Huber FRS, 1988 Nobel Prize Laureate, Chemistry *Excellent Cum Laude*. Universitat Autònoma de Barcelona (UAB)
1994-1998	B.Sci. Biochemistry, Universitat Autònoma de Barcelona (UAB)
1990-1995	B.Sci. Psychology (Neurosciences), Universitat Autònoma de Barcelona (UAB)

PROFESSIONAL EXPERIENCE

2015-	Associate Professor, Tenured Serra Húnter Fellow, Generalitat de Catalunya Dept. Biochemistry, Faculty Biology, UB
2014-	Tenure / Habilitazion Serra Húnter Programme, Generalitat de Catalunya
2014-	SGR - Research Group Recognized by AGAUR, Generalitat de Catalunya
2012-2015	Associate Professor (*Profesor Agregado Interino*) Dept. Biochemistry, Faculty Biology, UB
2012-	Tenure-accreditation Associate Professor (*Profesor Agregado*), Catalan University Quality Assurance Agency (AQU Catalunya). Dept. Biochemistry, Faculty Biology, UB
2012-	I3 Granted - Incentives for the Incorporation and Strengthening of Research Activity (PI3), Ministerio de Economía y Competitividad (MINECO)
2009-	Principal Investigator, Institute of Biomedicine (IBUB), UB
2008-	Ramón y Cajal Fellow. Ministerio de Economía y Competitividad (MINECO)
2008-	Marie Curie Fellow (IRG-International Reintegration Grant, EU)
2003-2007	Postdoctoral Fellow, University of California, San Francisco (UCSF) Prof. Robert J. Fletterick, Biochemistry & Biophysics Department, USA
2002-2003	Postdoctorate, Max-Planck-Institut fur Biochemie (MPI), Munich, Germany Prof. Dr. Robert Huber and Prof. Dr. Wolfram Bode
2000	Visiting Scientist. Prof. R. McGillivray, University of British Columbia, Canada
1998-2002	Ph.D. student at the Max-Planck-Institut fur Biochemie (MPI) Munich, Germany Prof. Dr. Robert Huber FRS, 1988 Nobel Prize Laureate, Chemistry
1997-1998	Rotational student. Dr. F. Azorín, CID-CSIC-Barcelona
1994-1995	Research Assistant. Profs. A. Martí and F. Balada, Dept. Psychobiology (UAB)
1994-1995	Rotational student. Prof. R. Bayés and X. Borrás, Dept. Psychology (UAB)
1993-1994	Rotational student. Prof. I. Morgado, Dept. of Psychobiology (UAB)

HONORS AND AWARDS

2014	Fellow Serra Húnter, Generalitat de Catalunya
2008-2012	Fellow Marie Curie IRG Reintegration, EU
2008-2012	Fellow Ramón y Cajal, MINECO Spain
2006-2007	Postdoctoral Fellowship Award, Herbert Boyer Foundation USA
2003-2006	Postdoctoral Fellowship Award, NIH-SPORE Prostate Cancer USA
2001-2002	Ph.D. Fellowship Award, EU fellowship (QLK3-CT-2001-01976)
1998-2001	Ph.D. Fellowship Award, EU fellowship (TMR-COSSAC, FMRXCT-98-0193)
2001	Paper of the Year Award - Biological Chemistry, 382: 1109-1110 (2.000€)
1999-2002	4 Crystal Awards, Max-Planck-Institut fur Biochemie (Germany)

PUBLICATIONS

IF=impact factor, C=citations, **Total citations=1812 H-index=21, i10-index=28** as in Google Scholar

A. MANUSCRIPTS IN SUBMISSION OR REVISION

46. Jiménez-Panizo A, Alegre-Martí A, Fettweis G, Abella M, Antón R, Tettey T, Schiltz RL, Johnson TA, Nuñez-Barrios I, Font-Díaz J, Caelles C, Valledor AF, Pérez P, Rojas AM, Fernández-Recio J, Presman DM, Hager GL, Fuentes-Prior P, **Estébanez-Perpiñá E**.
The multivalency of the glucocorticoid receptor ligand-binding domain explains its manifold physiological activities.

Nuclear Acids Research (IF=16.97), reviewed May 2022, rebuttal sent August **2022**.
Reference number: NAR-01322-M-2022.R1.

45. Alegre A, Jiménez A, Tebar A, Peralta N, Abella M, Antón R, Rojas AM, Fernández-Recio J, Rubio J, Aytes A,
Fuentes P, **Estébanez-Perpiñá E**. Structural determination of Androgen Receptor mutants linked to Prostate Cancer and Androgen Insensitivity Syndromes.
Science Advances (IF=14.136), reviewed July 2022, in rebuttal September **2022**.
Reference number: SCIADV-ade2175

44. Nadal M, Antón R, Dorca J, **Estébanez-Perpiñá E**, Tizzano E, Fuentes-Prior P. Three-dimensional structure of Sam68 RNA-binding domain: implications for the pathology of spinal muscular atrophy.
Protein Science (IF=6.725), Submitted July **2022**.
Reference number: PSI-22-12327.

43. Sevilla L, Pons O, Alegre A, **Estébanez-Perpiñá E**, Vitellius G, Pérez P. The mineralocorticoid receptor modulates genomic binding by glucocorticoid receptor in response to synthetic glucocorticoids in keratinocytes.
The FASEB J. (IF=5.191), reviewed, in rebuttal September **2022**.
Reference number: 2022-01199.

42. Jiménez-Panizo A, Alegre-Martí A, Abella M, Antón R, Font-Díaz J, Caelles C, Valledor AF, Fernández-Recio J, Presman DM, Hager GL, Fuentes-Prior P, **Estébanez-Perpiñá E**. Glucocorticoid receptor sensor site: a second binding site for therapeutic intervention. In preparation, **2022**.

41. Jiménez-Panizo A, Alegre-Martí A, Abella M, Antón R, Valledor AF, Rojas AM, Fernández-Recio J, Fuentes-Prior P, **Estébanez-Perpiñá E**. Androgen receptor and glucocorticoid receptor ligand-binding domain heterodimer.
In preparation, **2022**.

B. ARTICLES

2022

40. Vahid Sheikhhassani; Barbara Scalvini; Julian Ng; Laurens Heling; **Estébanez-Perpiñá E**.; Iain J. McEwan; Alireza Mashaghi. Topological dynamics of an intrinsically disordered N-terminal domain of the human androgen receptor. published **2022**.
Protein Science IF=6.725 C=1

39. Kandel P, Semerci F, Bajic A, Baluya D, Ma L, Chen K, Cao A, Phongmekhin N, Matinyan N, Jiménez-Panizo A, Chamakuri S, Rajis IO, MacKenzie KR, Fuentes P, **Estébanez-Perpiñá E**, Venken K, Winston D, Maletic-Savatic M. Compound x promotes hippocampal neurogenesis by acting as an endogenous ligand for nuclear receptor TLX.
Proceedings of the National Academy of Sciences 119 (13), 10.1073/pnas.2203038119, 119, 15, **2022**.
IF=11.2 C=6

2021

38. Jiménez-Panizo A, Alegre-Martí A, Fettweis G, Abella M, Antón R, Tettey T, Schiltz RL, Johnson TA, Nuñez-Barrios I, Font-Díaz J, Caelles C, Valledor AF, Pérez P, Rojas AM, Fernández-Recio J, Presman DM, Hager GL, Fuentes-Prior P, **Estébanez-Perpiñá E**. The multivalency of the glucocorticoid receptor ligand-binding domain explains its manifold physiological activities.
bioRxiv, **2021**. **C=1** doi: https://doi.org/10.1101/2021.10.01.462734

37. Sevilla LM, Jiménez-Panizo A, Alegre-Martí A, **Estébanez-Perpiñá E**, Caelles C, Pérez P.
Glucocorticoid Resistance: Interference between the Glucocorticoid Receptor and the MAPK Signaling Pathways.
Intl. J. Mol. Sci. (IJMS), 2021.
IF=5.923 C=8

36. **Estébanez-Perpiñá E**, Bevan C, McEwan I.
Eightly years of Targeting the Androgen Receptor Activity in Prostate Cancer: The Fight goes on.
Cancers, 13 (3), 509, 2021.

IF=11.09 C=14

2020

35. Díaz JF, Estébanez-Perpiñá E, Vivanco MdM, Pérez P, Aranda A, Castrillo A, Caelles C, Ricote M, Valledor AF. Nuclear receptors: lipid and hormone sensors with essential roles in the control of cancer development. **Seminars in Cancer Biology**. 2020.
IF=11.09 C=10

34. de Bosscher K, Desmet J, **Estébanez-Perpiñá E**, Brunsveld L.
Nuclear Receptor Crosstalk: defining the mechanisms of therapeutic innovation.
Nature Reviews Endocrinology (NRENDO). 2020. doi: 10.1038/s41574-020-0349-5.
IF=24.646 C=68

2019

33. Fuentes-Prior P, Rojas A, Hagler AT and **Estébanez-Perpiñá E**.
Diversity of Nuclear Receptor Quaternary Structures. 2019.
Trends in Biochemical Sciences (TiBS).18 (pii: S0968-0004), 188-9.
IF=16.889 C=12

32. Jiménez-Panizo A, Pérez P, Rojas A, Fuentes-Prior P and **Estébanez-Perpiñá E**.
Non-canonical dimerization of the Androgen Receptor and other Nuclear Receptors: Implications for Human Disease. 2019. **Endocrine-Related Cancer**. Review, June 01, 2019.
IF=5.331 C=18

2018

31. De Mol E, *et al.*, **Estébanez-Perpiñá E,** McEwan I, Nebreda AR, and Salvatella X.
Regulation of AR activity by transient interactions of its TAD with general transcription regulators. 2017.
Structure, S0969-2126(17)30360-X.
IF=5.618 C=38

2017

30. Nadal M, Prekovic S, Gallastegui N, *et al*, Claessens F, Fuentes-Prior P and **Estébanez-Perpiñá E**.
Structure of the homodimeric androgen receptor ligand-binding domain. 2017.
Nature Communications, 8, 14388.
IF=12.353 C=120

29. Claessens F, **Estébanez-Perpiñá E,** Fuentes-Prior P.
Description of the dimerization surface for the ligand binding domain of androgen receptor. 2017.
BioScientifica, 42.
IF=4.472

28. Claessens F, **Estébanez-Perpiñá E,** Fuentes-Prior P.
Description of the dimerization surface for the ligand binding domain of androgen receptor.
European Urology Supplement, 2017; 16 (3), e-165-e166.
IF=3.462

2016

27. De Mol E, *et al.*, **Estébanez-Perpiñá E,** McEwan I, Riera A, and Salvatella X.
EPI-001, a compound active against castration-resistant prostate cancer targets Tau5 of AR. 2016.
ACS Chemical Biology, 11(9):2499-505.
IF=5.331 C=96

2015

26. Gallastegui N, Mackinnon JA, Fletterick RJ, and **Estébanez-Perpiñá E.**
Advances in our Structural Understanding of Orphan Nuclear Receptors. 2015.
Trends in Biochemical Sciences (TiBS). 40, 25-35. Review.
IF=16.889 C=63

25. Gallastegui N, and **Estébanez-Perpiñá E**. Thinking Outside the Box: Alternative Binding Sites in the Ligand Binding Domain of Nuclear Receptors.
Book chapter. ISBN 978-3-319-18728-0, Springer, 2015. **C=2**

2014

24. Mackinnon JA, Gallastegui N, Osguthorpe DJ, Hagler AT, **Estébanez-Perpiñá E.**
Allosteric mechanisms of nuclear receptors: Insights from computational simulations.
Mol Cell Endocrinol. 2014: S0303-7207(14)00166-X. Review.
IF=4.405 C=27

23. Jehle K, *et al.*, **Estébanez-Perpiñá E,** Brown M and Cato ACB.
Coregulator control of AR action by a novel nuclear receptor-binding motif.

J. Biol. Chem., 2014; 289(13):8839-51.
IF=5.573 C=52

22. Gallastegui N, and **Estébanez-Perpiñá E**.
Androgen Receptor: Structural Biology, Genetics and Molecular Defects.
Book chapter. ISBN 978-1-62948-693-2, Nova Publishers, 2014. **C=2**

2012

21. Estruch SB, *et al.*, Lüders J, **Estébanez-Perpiñá E.** The oncoprotein BCL11A binds to orphan nuclear receptor TLX and potentiates its transrepressive function. PLoS One. 2012;7(6):e37963.
IF=4.411 C=28

20. Grosdidier S, *et al.*, Bevan C, Webb P, Fernández-Recio J, and **Estébanez-Perpiñá E.** Allosteric conversation in the androgen receptor ligand binding domain surfaces. Mol Endocrinol. 2012;26:1078-90.
IF=4.746 C=79

19. Buzon V, Carbó LR, Estruch SB, Fletterick RJ and **Estébanez-Perpiñá E.**
A conserved surface on the androgen receptor that allosterically regulates coactivator binding.
Mol Cell Endocrinol. 2012;348(2):394-402. Review.
IF=4.405 C=79

18. De Mol E, *et al.*, **Estebanez-Perpina E,** Bertoncini CW, Salvatella X. Characterization of the structural properties of the intrinsically disordered N-terminal domain of androgen receptor.
FEBS Journal, 2012; Sept, 279 (Suppl).
IF=4.001

2009

17. **Estébanez-Perpiñá E** and Robert J. Fletterick. The Androgen Receptor Coactivator Binding Interface.
Book chapter. ISBN 9780387691794, Springer 2009.
C=3

2008

16. Sala J. **Estébanez-Perpiñá E**, Balada F, Garau A, Martí-Carbonell MA.
Effects of adult dysthyroidism on the morphology of hippocampal neurons.
Behav Brain Res. 2008;188(2):348-54.
IF=3.629 C=49

15. Cruz L, **Estébanez-Perpiñá E**, *et al.*, Fletterick RJ, and England P. 6-Azido-7-nitro-1,4-dihydroquinoxaline-2,3-dione (ANQX) forms an irreversible bond to the active site of the GluR2 AMPA receptor. J Med Chem, 2008;51(18):5856-60.
IF=6.259 C=17

2007

14. **Estébanez-Perpiñá E**, Arnold LA, *et al.*, Shokat K, Guy RK and Fletterick, RJ.
A surface on the androgen receptor that allosterically regulates coactivator binding.
Proc Natl Acad Sci U S A. 2007; 104 (41):16074-9.
IF=10.50 C=295

13. **Estébanez-Perpiñá E**, Jouravel N, *et al.*, Guy RK and Fletterick RJ. Structural insight into the mode of action of a direct inhibitor of coregulator binding to the thyroid hormone receptor.
Mol Endocrinol. 2007;21(12):2919-28.
IF=4.746 C=69

12. Arnold LA, Kosinski A, **Estébanez-Perpiñá E**, Fletterick RJ, Guy RK. Inhibitors of the Interaction of a thyroid hormone receptor and coactivators: preliminary structure-activity relationships.
J Med Chem. 2007; 50(22):5269-80.
IF=6.259 C=46

2006

11. **Estébanez-Perpiñá E**, Jouravel N, and Fletterick RJ. Perspectives on designs of antiandrogens for prostate cancer. Exp Opin Drug Discov. 2007;2(10):1341-1355.
IF=4.421 C=12

33. Arnold LA, **Estébanez-Perpiñá E,** *et al.*, Fletterick RJ, Webb P, Guy RK. A high throughput screening method to identify small molecule inhibitors of the thyroid hormone receptor coactivator binding. Science STKE, 2006; 27; (341): pl3.
IF=8.00 C=35

2005

10. Arnold LA, **Estébanez-Perpiñá, E,** *et al.*, Fletterick RJ, and Guy RK.
Discovery of small molecule inhibitors of the interaction of thyroid hormone receptor with transcriptional coregulators. J. Biol. Chem., 2005; 280 (52): 43048-55.

IF=7.251 C=125

9. **Estébanez-Perpiñá E**, Moore J, Mar E, *et al.*, Baxter J, Fletterick RJ, and Guy KR.
The molecular mechanisms of coactivator utilization in ligand dependent transactivation by the androgen receptor. J. Biol. Chem., 2005, 280, 8060-8068.
IF=7.251 C=184

2003

8. **Estébanez-Perpiñá E,** Hink-Schauer C, Bode W. and Jenne D.
Crystal Structure of the Apoptosis-inducing Granzyme A Dimer.
Nature Structural and Molecular Biology (NSMB), 2003; 10 (7), 535-540.
IF=13.338 C=66

2002

7. **Estébanez-Perpiñá E**, Hink-Schauer C, Fuentes-Prior P, Bode, W and Jenne D.
The 2.2-Å Crystal Structure of Human Pro-granzyme K Reveals a Rigid Zymogen with Unusual Features. J. Biol. Chem., 2002; 277 (52): 50923-50933.
IF=7.251 C=67

6. **Estébanez-Perpiñá E**, Fuentes-Prior P, Belorgey D, *et al.*, Huber R, Rubin H, and Bode W.
Caspase Activator Human Granzyme B, Crystal Structure and Implications in Apoptosis.
Acta Cryst., 2002; A58 (Suppl, C280).
IF=2.286 C=2

2001

5. **Estébanez-Perpiñá E,** Bayés A, *et al.*, Huber R., Bode W, Avilés FX, and Reverter D.
Crystal structure of a novel midgut procarboxypeptidase from the cotton pest *Helicoverpa armigera.* J. Mol. Biol., 2001; 313, pp. 629-638.
IF=4.333 C=41

4. **Estébanez-Perpiñá E,** Fuentes-Prior P, Belorgey D, *et al.*, Huber R, Rubin H, and Bode W.
Crystal Structure of the Caspase Activator Human Granzyme B, a Proteinase highly Specific for an Asp-P1 Residue. FEBS Journal, 2001; July, 268 (Suppl).
IF=4.739

2000

3. **Estébanez-Perpiñá E**, Fuentes-Prior P, Belorgey D, *et al.*, Huber R, Rubin H, and Bode W.
Crystal Structure of the Caspase Activator Human Granzyme B, a Proteinase highly Specific for an Asp-P1 Residue. Biol. Chem. (Hoppe-Seyler), 2000; 381, 1203-1214.
IF=4.410 C=79

C. PATENTS

2. UK Patent Application Serial No. GB17001887.0.
Estébanez-Perpiñá E, Fuentes-Prior P, Claessens F. (2017).
Receptor.

1. US Patent Application Serial No. 10/705,165.
Fletterick RJ, **Estébanez-Perpiñá E,** Hur E, Pfaff SJ. (2003).
Inhibitors for Androgen Antagonist Refractory Prostate Cancer.
C=13

PROFESSIONAL SOCIETIES

1. European Society for Medical Oncology (ESMO)
2. The Endocrine Society (ES)
3. Spanish Biochemistry and Molecular Biology Society (SEBBM)
4. Federation of European Biochemical Societies (FEBS)

DISSEMINATION OF SCIENTIFIC RESULTS
A. TALKS - INVITED SPEAKER

63. URONCOMOL-RED Nacional Molecular Mechanisms of Cancer (Bilbao-Spain, Oct 2022)
62. NRRN Nuclear Receptor Research Network Benelux (Leiden-Netherlands, Nov 2020)
61. NURCAMEIN-RED Nacional de Receptores Nucleares (Bilbao-Spain, Oct 2020)
60. URONCOMOL-RED Nacional Molecular Mechanisms of Cancer (Bilbao-Spain, Nov 2020)
59. FASEB-Nuclear Receptors in Disease (West Palm Beach-Florida, USA, July 2020)
58. Nuclear Receptor Symposia (Sevilla-Spain, Jun 2020)
57. ENDO2020 Endocrine Society (San Francisco-USA, Mar 2020)
56. FUSION Nuclear Receptor Conference (Nassau, Bahamas, Feb 2020)
55. International Workshop on Sexual Dimorphism in Cancer (Lausanne, USA, April 2020)
54. NIH-National Institutes of Health (Bethesta, USA, Mar 2020)
53. MMCS-2019-Facing Novel Challenges in Drug Discovery (Barcelona-Spain, May 2019)
52. PacRim-2019 Prostate and Breast Cancers (Adelaide-Australia, March 2019)
51. CIBERONC and RED Nacional de Receptores Nucleares Joint Meeting (Madrid-Spain, Oct 2019)
50. EMBO Nuclear Receptors & Biological Networks (Crete, Greece, Sep 2018)
49. RED Nacional de Receptores Nucleares (Madrid-Spain, Nov 2018)
48. I3S- Instituto de Investigaçao e Inovaçao da Universidade do Porto (Oporto-Portugal, Jun 2018)
47. IBV-CSIC Spanish National Research Council (Valencia-Spain, Mar 2018)
46. Almirall Pharma (Barcelona-Spain, Feb 2018)
45. FUSION Nuclear Receptor Conference (Cancún, México, Feb 2018)
44. BAYER AG (Berlin-Germany, Jan 2018)
43. FEBS-SEBBM (Barcelona-Spain, Oct 2017)
42. Workshop on Macromolecular Crystallography (ALBA-CELLS, Barcelona-Spain, Oct 2017)
41. IBUB-Symposia on Biomedicine (Palau Heures-Barcelona-Spain, November 2017)
40. RED Nacional de Receptores Nucleares (Barcelona-Spain, Oct 2017)
39. BIT´s 10th Annual Cancer Congress – Defeating Cancer -2017 (Barcelona-Spain, Jun 2017)
38. Spanish Biophysical Society-2017 (Sevilla-Spain, Jun 2017)
37. RED Nacional de Receptores Nucleares (Madrid-Spain, Feb 2017)
36. Nuclear Receptor Symposia (Durham University-UK, Feb 2017)
35. ANDROGENS -2016 (Innsbruck-Austria, Sep 2016)
34. Androgen Receptor Symposium-Imperial College (London-UK, Jul 2016)
33. Societat Catalana de Biologia (Barcelona-Spain, Jun 2016)
32. RED Nacional de Receptores Nucleares (Barcelona-Spain, Jun 2016)
31. EMBO NRs From Molecules to Humans (Ajaccio, Corsica-France, Sep 2015)
30. GORDON Research Conferece Hormone-dependent Cancers-GRC (Maine-USA, Ago 2015)
29. Academia Nazionale dei Lincei - Allosteric Pharmacology (Rome-Italy, May 2015)
28. Nuclear Receptor Meeting, Generalitat Valenciana (Elche-Spain, Nov 2015)
27. Medivation Inc. (San Francisco-USA, Oct 2015)
26. Medivation Inc. (San Francisco-USA, Jan 2014)
25. BAYER-SCHERING Pharma (Berlin-Germany, Sept 2013)
24. ANDROGENS -2012 (Helsinki-Finland. Nov 2012)
23. Androgen Receptor Meeting (Leuven-Belgium, Dec 2012)
22. KEYSTONE – Nuclear Receptors Matrix Reloaded (Whistler-Canada, Apr 2012)
21. CNIO-Frontiers Meeting: Allosteric Regulation of Signalling (Madrid-Spain, Sep 2012)
20. EMBL-ESPRIT-User Meeting (EMBL-Heidelberg-Germany, Nov 2012)
19. BAYER-SCHERING Pharma (Berlin-Germany, Sep 2011)
18. CIBER-IBUB Intl. Nuclear Receptor Meeting (Barcelona-Spain, Set 2011)
17. ANDROGENS-2010 (Leuven-Belgium, Nov 2010)
16. EU-Marie Curie Actions Meeting (Barcelona-Spain, Jun 2010)
15. IBUB-Symposia on Biomedicine (Palau Heures-Barcelona-Spain, Jun 2010)
14. UCSF Symposia on Androgen Receptor and Prostate Cancer (San Francisco-USA, Mar 2010)

2009-2000: Postdoc & PhD student

13. *Red Temática Nacional: Estructura-Función de Proteínas* (CSIC-Valencia-Spain, Apr 2008)
12. Nuclear Receptor Simposium (CSIC-Valencia-Spain, Apr 2008)
10. COLD SPRING HARBOR-Nuclear Receptors: Bench to Bedside (CSH-USA, Nov 2006)
9. NIH-SPORE Retreat Prostate Cancer (San Francisco-USA, Apr 2006)
8. NIH-SPORE Retreat Prostate Cancer (San Francisco-USA, Apr 2004)
7. World Molecular Engineering Network (WMEN) (San José del Cabo-México, May 2005)
6. 38th Biophysical Chem., Molecular Biology and Cybernetics (Klosters-Switzerland, 2003)
5. Intl. 19th Winter School on Proteinases and their Inhibitors (Tiers, Italy, Feb 2001)
4. Intl. 18th Winter School on Proteinases and their Inhibitors (Tiers, Italy, Feb 2000)
3. Intl. 17th Winter School on Proteinases and their Inhibitors (Tiers, Italy, Feb 1999)
2. EU-COSSAC 3rd Intl. Catalytic Antibodies meeting (Athens-Greece, Jun 2001)
1. EU-COSSAC 2nd Intl. Catalytic Antibodies meeting (Trieste-Italy, Jun 2000)

B. POSTERS

57. EMBO NRs (Valletta, Malta, Sep 2022)
56. MetNet Meeting (Societat Catalana de Biologia-Barcelona-Spain, Feb 2022)
55. SMA Europe's 3rd International Scientific Congress on Spinal Muscular Atrophy (Barcelona-Spain, Nov 2021)
54. SEBBM-Sociedad Española de Bioquímica-XXXIV (Barcelona-Spain, Jul 2020)
53. Nuclear Receptor Fusion Conference (Nassau, Bahamas, Feb 2020)
52. SPETSES-FEBS – Nuclear Receptors -2019 (Spetses - Greece, Ago 2019)
51. Innstruct-2019 (1 poster) (Alcalá de Henares-Spain, May 2019)
50. Androgens-2018 (1 poster) (Edinburgh-UK, Oct 2018)
49. SPETSES-FEBS – Nuclear Receptors -2017 (Spetses - Greece, Ago 2017)
48. Androgens-2016 (2 posters) (Innsbruck-Austria, Sep 2016)
47. EMBO NRs From Molecules to Humans (4 posters) (Ajaccio, Corsica-France, Sep 2015)
46. GRC-Gordon Research Conferece Hormone-dependent Cancers (Maine-USA, Ago 2015)
45. Protein Society (Barcelona-Spain, Jun 2015)
44. COLD SPRING HARBOR: Nuclear Receptors & Disease (CSH-USA, Nov 2014)
43. Androgens-2014 (2 posters) (London-UK, Sep 2014)
42. CNIC-Energy Homeostasis and Metabolic Disease (Madrid-Spain, Nov 2014)
41. KEYSTONE. NRs: Biological Networks & Disease (New Mexico-USA, Jan 2014)
40. EMBO-Allosteric Interactions in Cell Signalling (Paris-France, May 2013)
39. EMBO-Computational Structural Biology (Hamburg-Germany, Apr 2013)
38. IRB BioMed-Frontiers in Mol Dynamics of Biomolecules (Barcelona-Spain, Nov 2013)
37. Androgens-2012 (2 posters) (Helsinki-Finland, Nov 2012)
36. CNIO-Frontiers Meeting: Allosteric Regulation of Cell Signalling (Madrid-Spain, Sep 2012)
35. FENS-ABCAM-Neurogenesis Intl. Meeting (Barcelona-Spain, Jun 2012)
34. Robert Huber X-Ray Symposia (Max-Planck-Institut für Biochemie-Germany, Febr 2012)
33. KEYSTONE – Nuclear Receptors Matrix Reloaded (Whistler-Canada, Apr 2012)
32. IRB BioMed-The Cytoskeleton in Human Disease (Barcelona-Spain, Mar 2013)
31. IRB BioMed-Normal and Tumor Stem Cells (Barcelona-Spain, Nov 2012)
30. SEBBM-Sociedad Española de Bioquímica-XXXIV (Barcelona-Spain, Set 2011)
29. EMBO-Nuclear Receptors (Sitges-Spain, Set 2011)
28. IRB-DNA Damage in Human Disease (Barcelona-Spain, May 2012)
27. Androgens 2010 (Leuven-Belgium, Nov 2010)
26. Nuclear Receptors Drug Discovery: Targets and Tools Informa (Berlin-Germany, 2010)
25. IRB-The Architecture of Life Symposia (Barcelona-Spain, Set 2009)
24. IRB BioMed Conference on Therapeutic Peptides (Barcelona-Spain, Oct 2009)
23. ICC Intl. Congress on Sirtuins (Barcelona-Spain, Oct 2009)
22. IRB-Targeting and Tinkering with Interaction Networks (Barcelona-Spain, Apr 2008)
21. NIH-SPORE Retreat Prostate Cancer (San Francisco-USA, Apr 2006)
20. NIH-SPORE Retreat Prostate Cancer (San Francisco-USA, Apr 2004)
19. IBC Drug Discovery Technology & Development Congress (Boston-USA, May 2005)
18. Molecular Medicine Tri-Conference. Medicinal Chemistry (San Francisco-USA, 2005)
17. The 17th West Coast Protein Crystallography Workshop (Asilomar-USA, 2005)
16. Protein Crystallography in Drug Discovery (South San Francisco-USA, 2005)
15. KEYSTONE-Androgen Receptor Keystone Symposia (Keystone-USA, 2004)
14. KEYSTONE-Nuclear Receptors: Orphan Brothers/Steroid Sisters (Keystone-USA, 2004)
13. COLD SPRING HARBOR-Programmed Cell Death (Cold Spring Harbor-USA, 2001)
12. Gordon Conference in Proteases and their Inhibitors (New Hampshire-USA, 2000)
11. XIX Congress of The Intl. Union Crystallography (IUCR) (Geneva-Switzerland, 2002)
10. SEBBM-Sociedad Española de Bioquímica (Lleida-Spain, Nov 2005)
9. International Proteolysis Society (IPS) (Munich-Germany, 2001)
8. 27th FEBS-Federation European Biochemistry Societies (Lisboa-Portugal, 2001)
7. 24th FEBS-Federation European Biochemistry Societies (Barcelona-Spain, 1996)
6. EU-COSSAC 3rd Intl. Catalytic Antibodies meeting (Athens-Greece, Jun 2001)
5. EU-COSSAC 2nd Intl. Catalytic Antibodies meeting (Trieste-Italy, Jun 2000)
4. Gesellschaft für Biochemie und Molekularbiologie (GBM) (Munich-Germany, 2000)
3. SEBBM-Sociedad Española de Bioquímica (Pamplona-Spain, Nov 1999)
2. Intl. Symposium on Proteinase inhibitors and Biological Control (Brdo-Slovenia, 1999)
1. International School of Crystallography of Macromolecules (CID-CSIC) (Barcelona, 1999)

FUNDING Total Raised

A. AS PRINCIPAL INVESTIGATOR (PI)

2022-2023 **PI: Estébanez-Perpiñá E**
50.000€ Valis Pharma USA Contract-1: Service Agreement

2021-2023 **PI: Estébanez-Perpiñá E**
144.000€ PDC - Proof of Concept - MINECO

2021-2021 **PI: Estébanez-Perpiñá E**
35.000€ Case Western University Contract-1: Service Agreement

2020-2020 **PI: Estébanez-Perpiñá E**
45.500€ GAT Therapeutics-Spain Contract-1: Service Agreement

2018-2020 **PI: Estébanez-Perpiñá E, Fuentes P**
100.000€ CaixaImpulse: Dimerization Inhibitors of Androgen Receptor

2019-2021 **PI: Arcaitz Carracedo, Estébanez-Perpiñá E, Joaquín Mateo, Álvaro Aytes**
20.500€ SAF2019-REDT-ORONCOMOL RED Nacional de Cáncer de Próstata (MINECO)

2018-2019 **PI: Estébanez-Perpiñá E**
20.000€ LLAVOR-Generalitat de Catalunya: Inhibitors of Androgen Receptor

2018-2019 **PI: Estébanez-Perpiñá E**
2.000€ Private donations

2018-2020 **PI: Estébanez-Perpiñá E**
125.000€ Plan Nacional I+D+i-BFU2017-86906-R: Structural Oncology of Androgen Receptor

2017-2019 **PI: Mercedes Ricote, Estébanez-Perpiñá E, Annabel Valledor, Carme Caelles**
19.000€ SAF2017-71878-REDT - RED Nacional de Receptores Nucleares (MINECO)

2017-2019 **PI: Estébanez-Perpiñá E, Fuentes P, Stracker T, Lüders J, Roig J**
42.000€ SGR - Research Group Recognized by AGAUR, Generalitat de Catalunya

2017-2019 **PI: Estébanez-Perpiñá E + Pablo Fuentes-Prior**
40.000€ Palobiofarma/Oncostellae-Spain Contract-2: Service Agreement
20.000€ Palobiofarma/Oncostellae-Spain Contract-1: Service Agreement

2018-2019 **PI: Estébanez-Perpiñá E**
23.000€ Greenaltech-Spain Contract-2: Service Agreement
10.000€ Greenaltech-Spain Contract-1: Service Agreement

2017-2018 **PI: Estébanez-Perpiñá E**
25.000€ Fons de Valorització F2I-Val, Fundació Bosch i Gimpera (UB)

2017-2018 **PI: Estébanez-Perpiñá E**
6.000€ Fons de Valorització F2I-MiR, Fundació Bosch i Gimpera (UB)

2016-2017 **PI: Estébanez-Perpiñá E**
10.000€ Bayer AG-GRANTS-4-TARGETS

2016-2017 **PI: Estébanez-Perpiñá E**
100.000€ IEDI-2016-00802 – Ayuda Incorporación Estable Doctores (MINECO)

2015-2017 **PI: Frank Claessens (KU Leuven) and Estébanez-Perpiñá E**
12.500€ Flemish Research Council - Scientific research community (WOG)

2015-2017 **PI: Estébanez-Perpiñá E**
7.000€ Private donations

2015-2017 **PI: Estébanez-Perpiñá E, Annabel Valledor, Carme Caelles**
36.000€ SAF2015-71878-REDT - RED Nacional de Receptores Nucleares (MINECO)

2015-2016 **PI: Estébanez-Perpiñá E**
28.800€ Bayer Healthcare-Germany Contract-3: service agreement

2015-2016 **PI: Estébanez-Perpiñá E**
8.000€ Orphagen Pharmaceuticals USA: service agreement

2014-2016 **PI: Estébanez-Perpiñá E**
100.000€ Medivation USA

2014-2015 **PI: Estébanez-Perpiñá E**
5.600€ Artax USA: protein supply

2014-2015 **PI: Estébanez-Perpiñá E**
10.000€ Orphagen Pharmaceuticals USA: service agreement

2014-2015 **PI: Estébanez-Perpiñá E**
16.500€ Marató de TV3-Rare Diseases

2013-2014 **PI: Estébanez-Perpiñá E**
25.000€ Bayer Healthcare-GRANTS-4-TARGETS

2011-2013 **PI: Estébanez-Perpiñá E**
72.600€ Plan Nacional I+D+i-SAF2011-29681: Structural characterization of AR coregulators

2011-2013 **PI: Estébanez-Perpiñá E**
134.000€ Marató de TV3-Rare Diseases: Identification of the AR aggregates causing SBMA

2011-2012 **PI: Estébanez-Perpiñá E**
30.000€ Pfizer-UK. Knowledge Transfer Agreement to UB

2012-2014 **PI: Estébanez-Perpiñá E**
8.000€ Orphagen Pharmaceuticals USA: protein supply

2012-2014 **PI: Estébanez-Perpiñá E**
3.000€ Shifa Pharmaceuticals USA: protein supply

2011-2013 **PI: Estébanez-Perpiñá E**
18.500€ Bayer Healthcare-Germany Contract-2: Service Agreement

2010-2012 **PI: Estébanez-Perpiñá E**
22.800€ Bayer Healthcare-Germany Contract-1: Service Agreement

2008-2012 **PI: Estébanez-Perpiñá E**
120.000€ Plan Nacional I+D+i-SAF2008-03562: Proteins binding to AR BF3

2009-2012 **PI: Estébanez-Perpiñá E**
120.000€ EU-Marie Curie IRG Grant-224812 (AR BF3)

2009-2012 **PI: Estébanez-Perpiñá E**
225.000€ Ramón y Cajal Award. RYC2007 (MINECO)

B. RAISED FOR LAB MEMBERS

2018-2019 Conference sponsorships & travel grants Grant: Jiménez-Panizo A
10.000€ FEBS-SPETSES-2019; EU-Innstruct-2019; CSIC-School Crystallography-2019

2014-2017 Juan de la Cierva-Postdoctoral Grant: Gallastegui N
55.000€ BFU2014-60135-P

2009-2013 FPI: Rodríguez-Carbó L (salary for 4 years)
55.000€ Associated to Plan Nacional I+D+i-SAF2008-03562 (AR BF3)

25.000€ 5 FPI Travel grants: EEBB-I1307243(2013); EEBB-44080(2011);BES-017130 (2009)

22.000€ Other grants: Asociación Española Contra Cáncer; Summer in the Park; Travel Grants.

C. OTHER FUNDING

2012-2020 **PI: Estébanez-Perpiñá E** ALBA Synchrotron (Spain)

2012-2013 **PI: Estébanez-Perpiñá E** Protein Crystallization Project (P-CUBE), Grenoble-EMBL

2009-2010 **PI: Estébanez-Perpiñá E** Barcelona Supercomputing Center (RES-BSC)

PROFESSIONAL SERVICES

A. Consultant

2011-2015 Scientific consultant for Medivation Inc.-USA
2006- Scientific consultant for Gerson Lehrman Group Councils-USA

B. *Ad hoc* Grant Reviewer

2012- French National Cancer Institute (INCa)
2006- AGAUR (Spanish-Catalan Scientific Grants' Agency)
2007- ANEP (National Evaluation and Foresight Agency)
2007- Reviewer for PNAS, Nature Comm, NSMB, JBC, JMB, MCE, Structure, Plos One, NURSA

C. Organizing Committees

2012-2016 IBUB Steering Committee (*Consell d´Administració*)
2011 Chair and Organizing Committee, IBUB International Symposium on Nuclear Receptors
2008- IBUB Seminars: R. Huber, C. Rochette, B. Berninger, A.T. Hagler, J. Schlessinger, D. Moras

D. Member of Ph.D. Thesis Examination Board

1. Laura del Amo (2011), student of the CID-CSIC, Spain
2. Christine Helsen (2012), student of the Katolische Universitaet Leuven, Belgium
3. Sergio Trillo (2014), student of the CID-CSIC, Spain
4. Mar López Pelegrín (2015), student of the CID-CSIC, Spain
5. Iñaki Ilarduya (2015), student of the CID-CSIC, Spain
6. Anna Belorusova (2015), student of IGBMC-Strasbourg University, France
7. Iracema Caballero (2020), student of the CID-CSIC, Spain
8. Laareb Mohammad (2021), student of UB-Chemistry, Spain
9. Fabian Zimmermann (2021), student of IRB Barcelona, Spain
10. Soraia Dos Santos (2022), student of the CID-CSIC, Spain

E. Thesis Advisory Commitees (TAC)

1. Claudia Millán Nebot-CID-CSIC
2. Isabel Mayayo-IRB Barcelona
3. Mireia Muriel-IRB Barcelona
4. Erick Hernández-Institute for Biomedical Research-Sant Pau
5. Giulio Chiesa-IRB Barcelona
6. Salvattore Scaffidi-IBUB
7. Míriam Martinez-IBUB
8. Guillermo Gutiérrez-IBUB

F. Commitees for Thesis Acceptance in the Biotechnology Master Program

G. Faculty of Biology, Treball Final de Grau Commitees (TFG)

TRAINING EXPERIENCE

A. Ph.D. THESIS

4. Andrea Alegre-Martí Ph.D. Thesis defense date: Dec 2023.
Crystal Structure of Androgen Receptor Mutants linked to Prostate Cancer.

3. Alba Jiménez-Panizo Ph.D. Thesis defense date: 14th December 2021.
The multivalency of the glucocorticoid receptor ligand-binding domain explains its manifold physiological activities.

2. Eugènia Ruiz-Cánovas Ph.D. Thesis defense date: 10th December 2018.
Co-tutored with Dr. Jaumé Mercadé (Greenaltech).
Title: Compound F, a novel nuclear receptor modulator and its potential application on hematologic malignancies.

1. Laia Rodríguez-Carbó Ph.D. Thesis defense date: 25th January 2016.
Grant: FPI-MINECO, 2010-2015
Title: Characterization of alternative therapeutic sites on the androgen receptor and novel protein-protein associations.

B. MASTER THESIS DIRECTED (1 Year)
11. Leonor Cea, UB Biochemistry, 2022-2023
10. Ana Alicia Martín, UB Biochemistry, 2021-2022
9. Andrea Alegre, UB Biochemistry, 2018-2019
8. Alba Jiménez, UB Biomedicine, 2017-2018
7. Edwin Hualpa, Perú Master Grant-UB Biotechnology, 2014-2015
6. Irene Neuhauser, Erasmus Austria-UB Biotechnology, 2013-2014
5. Catalina Royuela, Erasmus Austria-UB Biotechnology, 2013-2014
4. Sara Busquets, UB Biomedicine, 2011-2012
3. Julie Briot, Erasmus France-UB Biotechnology, 2010-2011
2. Imke Baade, Erasmus Germany-UB Biotechnology, 2010-2011
1. Lukas Najdekr, Erasmus Czeck Republik-Olomouc Univ, 2009-2010

C. BACHELOR THESIS DIRECTED (PI+PII+TFG) (6 Months)
12. Vinyet Esteve, UB Biochemistry, 2022-2023
12. Jana Bagán, UB Biochemistry, 2021-2022
11. Mar Moré, UB Biochemistry, 2019-2020
10. Bernat París, UB Biochemistry, 2019-2020
9. Irene Rico, UB Chemistry, 2019-2020
8. Andrea Alegre, UB Biochemistry, 2018-2019
7. Xavier Calvo, UB Biochemistry, 2017-2018
6. Alba Jiménez, UB Biomedicine, 2016-2017
5. Laia Moner, UB Pharmacy, 2015-2016
4. Maria Gómez-Fabra, UB Biochemistry, 2014-2015
3. Guillem López, UB Biotechnology, 2013-2014
2. Barbora Pastorkova, Erasmus Czeck Republik-Olomouc Univ, 2012-2013
1. Lenka Schorova, Erasmus Czeck Republik-Olomouc Univ, 2011-2012

D. POSTDOC SUPERVISION
1. Nerea Gallastegui, Juan de la Cierva-MINECO, 2013-2016
2. Cristina Arimany, 2014-2015
3. Victor Buzon, La Marató-TV3, 2011-2013

E. TECHNICIANS
2. Montse Abella, 2016 - present
1. Karolina Zielinska, 2012-2013

F. SUMMER ROTATIONAL STUDENTS (3 Months)
7. Lena Hipp, Erasmus Germany, 2014-2015
6. Tom Ajime, Erasmus Mundus MCAL-UB, 2014
5. Laia Moner, Grant *Passa Estiu al PCB*, 2013
4. Silvia Llonch, Grant *Passa Estiu al PCB*, 2012
3. Sara Busquets, Grant *Passa Estiu al PCB*, 2011
2. Alicia Chau, USA, 2011
1. Petra Klevkova, Erasmus Czeck Republik-Olomouc Univ., 2011

USA & Germany - Former Supervised Students
1. Coordination of SPORE and Shifa projects: supervision of 2 technicians (Elena Mar, Phuong Nguyen), 3 rotation students (Leslie Cruz, Molly Darragh, Kris Kuchenbecker) and 2 postdocs at UCSF-USA (Ray Bateman; Alex Arnold)

2. Coordination of EU-COSSAC project: supervision of 1 technician (Marianne Braun) and 1 postdoc (Clara Hink-Schauer) at the Max Planck-Institute, Germany

TEACHING EXPERIENCE
Hereby, a brief description of my teaching appointments:

2021-2022 **GREC=AA** **Hores: Docència=193,5h (700h PDA) Gestió=5h**
-Tutor 2 PhD (AJPanizo; AAlegre), 1 technician (MAbella), 1 internal PI/PII/TFG (Jbagán), 1 TFM (AAMartín)
-Degree Biochemistry: Professor and coordinator: *Drug Design and Evaluation of Bioactive Molecules*
-Master Biotechnology: Professor: *Macromolecular Structure; Research Seminars*

2020-2021 **GREC=AA** **Hores: Docència=180h (700h PDA) Gestió=5h**
-Tutor 2 PhD (AJPanizo; AAlegre), 1 technician (MAbella), 1 internal PI/PII/TFG
-Degree Biochemistry: Professor and coordinator: *Drug Design and Evaluation of Bioactive Molecules*
-Master Biotechnology: Professor: *Macromolecular Structure; Research Seminars*

2019-2020 **GREC=AA** **Hores: Docència=135h (700h PDA) Gestió=5h**
-Tutor 1 PhD (AJPanizo), 1 Máster (AAlegre), 1 technician (MAbella), 3 internal PI/PII/TFG (MMoré; BParís; IRico)
-Degree Biochemistry: Professor and coordinator: *Drug Design and Evaluation of Bioactive Molecules*
-Master Biotechnology: Professor: *Macromolecular Structure; Research Seminars*

2018-2019 **GREC=AA** **Hores: Docència=125h (532h PDA) Gestió=5h**
-Directing 1 postdoc (MNadal), 2 PhD (AJPanizo; ERuiz), 1 technician (MAbella), 1 internal PI/PII/TFG (AAlegre)
-Degree Biochemistry: Professor and coordinator: *Drug Design and Evaluation of Bioactive Molecules*
-Master Biotechnology: Professor: *Macromolecular Structure; Research Seminars*

2017-2018 **GREC=AB** **Hores: Docència=125h (532h PDA) Gestió=5h**
-Directing 1 postdoc (MNadal), 1 PhD (ERuiz), 1 technician (MAbella), 1 TFM student, 1 internal PI/PII/TFG student
-Degree Biochemistry: Professor and coordinator: *Drug Design and Evaluation of Bioactive Molecules*
-Master Biotechnology: Professor: *Macromolecular Structure; Research Seminars*

2016-2017 **GREC=AB** **Hores: Docència=120h (532h PDA) Gestió=10h**
-Directing 1 postdoc, 1 PhD, 1 technician, 2 internal PI/PII/TFG
-Degree Biochemistry: Professor and coordinator: *Drug Design and Evaluation of Bioactive Molecules*
-Master Biotechnology: Professor: *Macromolecular Structure; Research Seminars*

2015-2016 **GREC=AB** **Hores: Docència 274h (784h PDA) Gestió=10h**
Subject coordinator: Drug Design and Evaluation of Bioactive Molecules
-Same teaching duties as 2014-2015 as detailed below
-Tutoring of 4 students doing Practicums I, II and TFG
-Directing 2 postdocs, 1 technician

2014-2015 **GREC=AB** **Hores: Docència 250h (883h PDA) Gestió=14h**
-New subject (AQU approved): Degree of Biochemistry:
Subject coordinator: Drug Design and Evaluation of Bioactive Molecules
-Same teaching duties as 2013-2014 as detailed below
-Tutoring of 4 students doing Practicums I, II and TFG
-Directing 1 Master Thesis, 2 postdocs, 1 technician

2013-2014 **GREC=BC** **Hores: Docència 254h (901h PDA) Gestió=4h**
-New subject (AQU approved): Degree of Biochemistry:
Subject coordinator: Drug Design and Evaluation of Bioactive Molecules
-Same teaching duties as 2012-2013 as detailed below
-Tutoring of 4 students doing Practicums I, II and TFG
-Directing 2 Master Thesis, 1 postdocs, 1 Erasmus

2012-2013 **GREC=BC** **Hores: Docència 252h (803h PDA) Gestió=8h**
-Professor Masters: 1.Biotechnology and 2.Biomedicine
-Professor Degrees: 1. Biochemistry; 2.Biology; 3.Biotechnology; 4.Biomedicine
-Tutoring of 4 students doing Practicums I, II and TFG
-Directing 1 Ph.D. Thesis, 2 postdocs, 1 Erasmus and 1 technician

2011-2012 **GREC=BC** **Total: 252h (803h PDA)**
-Professor Masters: 1.Biotechnology; 2.Biomedicine; 3.Neurosciences
-Professor Degrees: 1. Biochemistry; 2.Biology; 3.Biotechnology; 4.Biomedicine
-Directing 1 Ph.D. Thesis, 1 postdoc, 1 Master student, 4 Erasmus, and 1 technician

2010-2011 **RYC** **Total=87h**
-Professor Masters: 1.Biotechnology; 2. Erasmus Mundus MQAL (*Innovació Docent*)
-Directing 1 Ph.D. Thesis, 1 postdoc, 1 Master student, 5 Erasmus, and 2 summer students

2009-2010 **RYC** **Total=80h**
-Professor Masters: 1.Biotechnology
-Professor Degree: 1.Biochemistry; 2.Biology

2008-2009 **RYC** **Total=60h**
-Professor Masters: 1.Biotechnology

1994-1995 **Total=10 hours**: substitute for the Dean of F. Psychology UAB Prof. S.Martí-Carbonell

CONTINUING EDUCATION: PROFESSIONAL DEVELOPMENTAL PROGRAMS

1. CAIXA IMPULSE TRAINING COURSE (2018).
Weeks: 4. Barcelona, Palau Macaya and La Caixa Diagonal Headquarters.
Valorization process, Funding, Protecting your Asset, Communication Skills, Best Practices, Technology Transfer, Intellectual Property (IP) Strategy, Product Development, Commercialization, Pitch.

2. CLAUS PER BIOEMPENDRE (2017 / 2018 / 2019). ICE-FBG-University of Barcelona.
Hours: 10h/year. Barcelona.

3. SISTEMA ACREDITACIÓN DE CUERPOS DOCENTES (2015). ICE-University of Barcelona.
Contents: Guia pràctica per a la Sol.licitut de Trams d´Investigació.
Hours: 5h. Barcelona.

4. CONFLICT MANAGEMENT AND SOLVING (2014). ICE-University of Barcelona.
Hours: 10h. Barcelona.

5. EMBO-LEADERSHIP SCULPTOR LAB MANAGEMENT FOR GROUP LEADERS (2013).
The art of leadership, fewer conflicts and more results.
Hours: 30h. Leinen bei Heidelberg, Germany.
Contents: Leadership types, the PI/ group leader role, the impact of cultural differences in a lab, communication skills, working with values, coaching, team dynamics, conflict solving in a lab, giving feedback and criticism, motivation, running effective group meetings, the importance of delegation, how to avoid taking problems from group members, interview preparation and key questions, problem solving-tools, the impact of personality type on leadership.

6. PATENTS IN BIOMEDICINE (2011). Prof. Pascual Segura. CRG, Barcelona, Spain.

7. PLA DE FORMACIÓ GESTIÓ ACADÈMICA I DE RECERCA (2011-2012).
ICE-University of Barcelona.
Organizers Prof. Joan Guàrdia Olmos and Prof. Teresa Pagès.
Hours: 60h. Barcelona (Spain)
Contents:
Mòdul General (UNI2010035:4h)
- Les claus de la Universitat actual. Dr. Juan Tugores.
- Elements propis dels Sistemes de Qualitat Universitària. Dra Gemma Rauret.
- Bases per a la Gestió Estratègica Universitària. Dr. Guadalberto Buela.
- El Marc General de la Recerca. Dra. Montserrat Tomer.

Mòdul Coneixement Normatiu de la UB (UNI2010036:6h)
- Normatives Acadèmiques. Dra Teresa Anguera.
- Normatives Professorat. Dr. Manel Viladevall.
- Polítiques d´Estudiants i Linguïstica. Dra Gemma Fonrodona.
- Altres Normatives. Dr. Jordi García.

Mòdul Gestió de Grups i Projectes de Recerca (UNI2010037:6h)
- L´Avaluació dels Projectes de Recerca. Dra Josep Maria Fullola.
- La Gestió de la Recerca. Dr. Marçal Pastor i Dr. Jordi Alberch Vié

Mòdul Mediació Conflictes/Habilitats directives i de lideratge (UNI2010038:14h)
- Tècniques i habilitats mediadores prevenció i gestió conflictes. Dra. Gloria Novel
- Habilitats directives. MetaForum Sr. José Luis Alonso.

Mòdul Tècniques control qualitat universitat/Auditories qualitat plans estudis (UNI2010039:6h)
Mòdul Tècniques direcció estratègica/Gestió de RRHH per al professorat (UNI2010040:6 h)
- Processos Comunicació i Gestió Reunions. Dr. Jaume Llacuna.
- Gestió de RRHH pel Professorat. Dr. Claudi Mans.

Mòdul Tècniques de Comunicació (UNI2010041:6h)
- Direcció Estratègica a la Universitat. Dr. Miquel Bonet.
- Comunicació per Directius. Dra. Estrella Montoliu.

Mòdul Gestió transferència tecnologia i activitats dels Parcs Científics (UNI2010042:6h)
- Projectes en Xarxa i Transferència de Tecnologia. Dr. Josep Samitier.
- Gestió de la Transferència de Tecnologia. Sra. Carme Verdaguer.
- El Parcs Científic UB. Dr. Fernando Albericio.
- Gestió de la Recerc com Motor de la Transferència. Dr. Joan Guinovart.

COLLABORATIONS

1. Pablo Fuentes-Prior, Sant Pau, Spain
2. Arnie T. Hagler, University of Massachussets, USA
3. Gordon Hager, NIH-National Institute of Cancer, Bethesda, USA
4. Diego Presman, NIH-National Institute of Cancer, Bethesda, USA
5. Paloma Pérez, CSIC Valencia, Spain
6. Annabel Valledor, University of Barcelona
7. Carme Caelles, University of Barcelona
8. Álvaro Aytes, Idibell, Barcelona, Spain
9. Jun Xu, Sat-Yan Sen University, China
10. Natacha Rochel, IGBMC- Illkirch, France
11. Jens Lüders, IRB, Barcelona, Spain
12. Juan Fernández-Recio, Barcelona Supercomputing Center, Barcelona, Spain
13. Ana Rojas, CSIC-Sevilla, Spain
14. Jaime Rubio, University of Barcelona
15. Alireza Tabari, Eindhoven University, The Netherlands

LANGUAGES

1. Catalan: native speaker
2. Spanish: native speaker
3. English: native speaker level, Cambridge Certificate of Proficiency in English, UK
4. German: spoken: very fluent, written: intermediate level/Mittlere Stufe, Inlingua, Munich, Germany
5. French: beginner level, Alliance Française San Francisco, USA
6. Arabic: beginner level, Official School of Languages, Barcelona, USA
7. Hebrew: beginner level, Barcelona, USA

EXPERTISE

-Protein structure–function relationship analysis using different biophysical, biochemical and functional techniques of different major human protein targets implicated in pathology.

-Structural Biology expertise (X-ray crystallography), protein expression and purification, computational chemistry and high-thoroughput X-ray crystallography.

-Trained user of large synchrotron radiation facilities (Europe: ALBA-CELLS, ESRF, DESY; USA: ALS-Berkeley) and supercomputers (Marenostrum-BSC; Altamira-Univ. Cantabria).

-Neurosciences expertise. Animal surgery (adult rats): brain stereotaxy, perfusions, intra-craneal canule implantation, ultra-microtome, brain extraction, histology of hippocampal neurons, behavioral techniques.

(1) Human steroid nuclear receptors (NRs)

Androgen Receptor (AR), Thyroid Receptor (TR), Glucocorticoid Receptor (GR), Estrogen alpha and beta Receptors (ERa, ERb), Tailess Orphan Receptor (TLX)

Elucidation of the structural mechanisms underlying major human NR-related pathologies:

- Metastatic-resistant Prostate Cancer
- Androgen Insensitivity Syndromes (AIS)
- Spinal and Bulbar Muscular Atrophy – Kennedy´s disease (SBMA)
- Brain tumor: Glioblastoma

-Structure-based drug design:

- Allosteric modulators of Nuclear Receptors
- Type-selective surface-inhibitors of key AR and TR protein-protein interactions

(2) Human serine-proteases Granzymes A, B and K

Elucidation of the structural mechanisms underlying major human Gzm-related pathologies:

- Rheumathoid arthritis (Granzyme A), other autoimmune diseases
- Induction of Apoptosis triggered by Granzyme A and B

(3) Human ionotropic AMPA receptor

-Structure/function relationship of human AMPA and photoinducible inhibitors
-Drug-discovery of drugs facilitating learning and memory

(4) Carboxypeptidases human/insect.

-Structure-based drug design for drugs against insect pests